Trial Profile
A Multicenter, Randomized, Open-label, Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM)
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Asunercept (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors CANbridge Pharmaceuticals
- 07 Jan 2022 According to ClinicalTrials.gov record, the recruitment status of this study is unknown because the information has not been verified recently (Last verified 15 November 2018).
- 26 Aug 2019 According to the CANbridge Pharmaceuticals website, the company was formerly called as CANbridge Life Sciences.
- 15 Nov 2018 Status changed from planning to not yet recruiting.